The U.S. Food and Drug Administration has approved a new daily pill for attention-deficit hyperactivity disorder, marking the first time a medication from an entirely new drug class has reached the market for the condition in years. The decision offers millions of patients a fresh option beyond traditional stimulants and existing non-stimulant therapies.
The drug, called Simtriyo (centanafadine), is the first approved norepinephrine, dopamine, serotonin reuptake inhibitor in the United States. It is indicated for patients aged 6 years and older who weigh at least 20 kilograms. The approval was supported by four Phase 3 clinical trials. In two studies focused on adults, the drug significantly improved ADHD symptoms compared to a placebo, with benefits appearing as early as week one and lasting throughout six weeks of treatment. Two additional trials in pediatric and adolescent patients also showed meaningful symptom improvement.
The FDA has placed a boxed warning on Simtriyo, flagging risks of suicidal ideation and behaviors, as well as potential for abuse, misuse, and addiction. The drug’s controlled substance scheduling is still pending review by the U.S. Drug Enforcement Agency. Otsuka Pharmaceutical, the drug’s developer, said it expects to make Simtriyo available later this year after the DEA completes its evaluation.
What This Means for Patients
The ADHD treatment market remains large and, according to analysts, under-penetrated, particularly for non-stimulant options. Many patients and families have sought alternatives to traditional stimulant therapies due to side effects, abuse concerns, or lack of response. Simtriyo’s unique mechanism of action, targeting three neurotransmitter systems instead of one or two, may offer a different profile. Analysts at Jefferies noted that even if the drug receives less restrictive scheduling by the DEA, it could be positioned between traditional stimulants and existing non-stimulants, potentially giving it a distinct advantage.
Otsuka has previously forecast peak sales for Simtriyo of more than ¥100 billion, roughly $615 million. The company views the approval as a major milestone in its central nervous system portfolio. For patients and clinicians, the arrival of a new drug class represents a long-awaited expansion of treatment choices, especially for those who have struggled with current options.